Market capitalization | $50.00k |
Enterprise Value | $274.17m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.27 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | -1.93% |
Revenue (TTM) Revenue | $64.27m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast NantHealth, Inc.:
1 Analyst has issued a forecast NantHealth, Inc.:
Sep '23 |
+/-
%
|
||
Revenue | 64 64 |
2%
2%
|
|
Gross Profit | 35 35 |
7%
7%
|
|
EBITDA | -24 -24 |
30%
30%
|
EBIT (Operating Income) EBIT | -39 -39 |
22%
22%
|
Net Profit | -70 -70 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NantHealth, Inc. is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer in United States, the United Kingdom, Singapore, and Canada. Its solutions include empower treatment decisions; improve patient outcomes; validate treatment options; enable high-quality care; lower costs; ensure appropriate reimbursement; and streamline implementation and deployment. The company was founded by Patrick Soon-Shiong in July 2010 and is headquartered in Culver City, CA.
Head office | United States |
CEO | R. Naseem |
Founded | 2010 |
Website | www.nanthealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.